Since biodegradable screws eliminate the need for removal surgery, it can be assumed that the number of complications will decrease, based on the premise that surgeries in general always carry a risk of complications.
The US market operates primarily on a fee-for-service basis as you mentioned, but a reduction in total costs should interest the public sector both in the US and elsewhere.
Yeah, I have to open my mouth as well, since Iâve been following this since the early days of the FDA clearance application. The offering ended up being quite successful and the share price has started a slight upward trend. Personally, I have very mixed feelings about the share issue arrangement. On one hand, I try to understand why the FIN-FSA (Finanssivalvonta) decided to grant an exemption from the mandatory tender offer obligation; perhaps it can be justified as being in the best interest of the company. It seems that in this case, as is often the case, securing the companyâs operating conditions takes precedence over the interests of minority shareholders. Whatâs happening now is that the largest owner is able to bypass the tender offer obligation with the blessing of the FIN-FSA. I believe we will soon see a mandatory offer, which will naturally be close to the subscription price and which few will accept. This way, the largest owner can more freely increase their stake further until the next tender offer threshold. This is essentially a textbook corporate cornering. Itâs a shame for retail investors because determining the true value of the company is so difficult. Below are two quotes from the companyâs announcements regarding the exemption; especially the latter only reinforces my view that the largest owner intends to increase their holding in the future as well.
Quote from the announcement regarding the exemption (March 26):
âThe condition for the exemption is that Stephen Industries Inc Oy, Kustaa Poutiainen, or persons acting in concert with them do not acquire or subscribe for more shares in Bioretec or otherwise increase their voting rights in Bioretec after exceeding the tender offer threshold.â
In the flagging notification published on April 28, the same thing is stated in different words:
âExceeding the 30 percent tender offer threshold does not therefore trigger an obligation for Kustaa Poutiainen or Stephen Industries Inc Oy to make a mandatory public tender offer until Stephen Industries Inc Oy, Kustaa Poutiainen, or persons acting in concert with them acquire or subscribe for more shares in Bioretec or otherwise increase their voting rights in Bioretec.â
Here are Anttiâs comments on Bioretecâs change negotiations, through which the company seeks additional savings.
Stock Exchange Release
Bioretec Ltd Company Release 2 June 2026 at 1:25 p.m. EEST
Person subject to the notification requirement
Name: Jordy Winters
Position: Other senior management
Nature of the transaction: ACQUISITION
Volume: 1,000,000 Average price: 0.0224 EUR
Bioretec announces that its CEO Sarah van Hellenberg Hubar-Fisher has purchased a total of 1,660,000 shares of the company at a price of 0.02258 euros per share. She purchased the shares for a total of 37,482.20 euros.
According to information published by the company at the end of May, she did not own any Bioretec shares prior to these transactions.
CFO Paavola also bought a stack of shares some time ago. Quite a few insiders have been buying.
So at least within the company, faith is strong. Itâs a bit reassuring 